International pharmaceutical spending controls: France, Germany, Sweden, and the United Kingdom.
France, Germany, Sweden, and the United Kingdom each use different types of policies for controlling prescription drug spending. Until recent years, these policies have relied heavily on regulating prices charged by drug manufacturers, with different systems providing varying degrees of pricing freedom. While these policies appear to have brought some degree of price restraint, they have not prevented continued growth in prescription drug spending. As a result, each country is supplementing its policies with measures aimed at physicians and consumers and targeted at reducing a perceived over-utilization of pharmaceutical products.
KPMG Peat Marwick, Washington, DC 20036.
D J
DJ
Gross
J
J
Ratner
J
J
Perez
S L
SL
Glavin
D003363:Cost Control / Q000331:legislation & jurisprudence; D017047:Cost Sharing; D016527:Drug Costs / Q000331:legislation & jurisprudence*; D004345:Drug Industry / Q000191:economics* / Q000331:legislation & jurisprudence; D004363:Drug Utilization / Q000639:trends; D004608:Eligibility Determination; D005602:France; D005858:Germany; D006291:Health Policy / Q000191:economics* / Q000331:legislation & jurisprudence; D007250:Inflation, Economic / Q000639:trends; D007356:Insurance, Pharmaceutical Services / Q000706:statistics & numerical data*; D009313:National Health Programs / Q000191:economics; D013222:State Medicine / Q000191:economics; D013548:Sweden; D006113:United Kingdom